Detection and Characterization of Methylated Circulating Tumor DNA in Gastric Cancer DOI Open Access
Seung Young Seo, Sang Hee Youn, Jin‐Han Bae

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(13), С. 7377 - 7377

Опубликована: Июль 5, 2024

Gastric cancer is the fifth most common disease in world and fourth cause of death. It diagnosed through esophagogastroduodenoscopy with biopsy; however, there are limitations finding lesions early stages. Recently, research has been actively conducted to use liquid biopsy diagnose various cancers, including gastric cancer. Various substances derived from reflected blood. By analyzing these substances, it was expected that not only presence or absence but also type can be diagnosed. However, amount extremely small, even have variables depending on characteristics individual To overcome these, we collected methylated DNA fragments using MeDIP compared them normal plasma characterize tissue patients' plasma. We attempted blood As a result, confirmed consistency between approximately 41.2% found possibility diagnosing characterizing SFR 5'end-motif analysis.

Язык: Английский

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine DOI Creative Commons
Ying Bao,

Dejing Zhang,

Huihui� Guo

и другие.

Cancer Science, Год журнала: 2024, Номер 115(4), С. 1060 - 1072

Опубликована: Фев. 3, 2024

Abstract Liquid biopsy is emerging as a pivotal tool in precision oncology, offering noninvasive and comprehensive approach to cancer diagnostics management. By harnessing biofluids such blood, urine, saliva, cerebrospinal fluid, pleural effusions, this technique profiles key biomarkers including circulating tumor DNA, cells, microRNAs, extracellular vesicles. This review discusses the extended scope of liquid biopsy, highlighting its indispensable role enhancing patient outcomes through early detection, continuous monitoring, tailored therapy. While advantages are notable, we also address challenges, emphasizing necessity for precision, cost‐effectiveness, standardized methodologies broader application. The future trajectory set expand reach personalized medicine, fueled by technological advancements collaborative research.

Язык: Английский

Процитировано

20
The omics technologies and liquid biopsies: Advantages, limitations, applications DOI Creative Commons
Daniele Magro,

Marika Venezia,

Carmela Rita Balistreri

и другие.

Medicine in Omics, Год журнала: 2024, Номер 11, С. 100039 - 100039

Опубликована: Май 21, 2024

Over the last few years, development of so-called omics technologies has greatly contributed to discovery new biomarkers and targets, embracing various fields from diagnostics therapy contributing meliorate advance precision personalized medicine. In addition classic omics, including genomics, transcriptomics, proteomics, metabolomics, newer-generation their platforms, such as microbiomics nutrigenomics, are emerging. parallel, use liquid biopsies, optimal biological samples, consisting in fluids (i.e. blood, saliva, urine) easy collect, whose components (cells, nucleic acids, exosome) can be analysed using throughput techniques, is becoming an attractive, because enables extrapolation big data via multi-omics technologies. Here, we report a brief description discussion technologies, by evidencing applications eventual limitations.

Язык: Английский

Процитировано

11
The Potential of cfDNA as Biomarker: Opportunities and Challenges for Neurodegenerative Diseases DOI Creative Commons
Şeyma Aydın, Selçuk Özdemir, Ahmet Adıgüzel

и другие.

Journal of Molecular Neuroscience, Год журнала: 2025, Номер 75(1)

Опубликована: Март 13, 2025

Abstract Neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s (PD), multiple sclerosis (MS), and amyotrophic lateral (ALS), are characterized by the progressive gradual degeneration of neurons. The prevalence rates these disorders rise significantly with age. As life spans continue to increase in many countries, number cases is expected grow foreseeable future. Early precise diagnosis, along appropriate surveillance, continues pose a challenge. high heterogeneity neurodegenerative diseases calls for more accurate definitive biomarkers improve clinical therapy. Cell-free DNA (cfDNA), fragmented released into bodily fluids via apoptosis, necrosis, or active secretion, has emerged as promising non-invasive diagnostic tool various diseases. cfDNA can serve an indicator ongoing cellular damage mortality, neuronal loss, may provide valuable insights processes, progression, therapeutic responses. This review will first cover key aspects then examine recent advances its potential use biomarker disorders.

Язык: Английский

Процитировано

1
Deep Learning-Based, Multiclass Approach to Cancer Classification on Liquid Biopsy Data DOI Creative Commons
Maksym A. Jopek, Krzysztof Pastuszak, Sebastian Cygert

и другие.

IEEE Journal of Translational Engineering in Health and Medicine, Год журнала: 2024, Номер 12, С. 306 - 313

Опубликована: Янв. 1, 2024

Objective : The field of cancer diagnostics has been revolutionized by liquid biopsies, which offer a bridge between laboratory research and clinical settings. These tests are less invasive than traditional biopsies more convenient routine imaging methods. Liquid allow studying tumor-derived markers in bodily fluids, enabling the development precise diagnostic for screening, disease monitoring, therapy personalization. This study presents multiclass approach based on deep learning to analyze classify diseases blood platelet RNA. Its primary objective is enhance cancer-type diagnosis settings leveraging power combined with high-throughput sequencing biopsy. Ultimately, demonstrates potential this accurately identify patient's type cancer. xmlns:xlink="http://www.w3.org/1999/xlink">Methods developed method classifies patients using heatmap images, generated gene expression arranged according Kyoto Encyclopedia Genes Genomes pathways. images represent samples ovarian cancer, endometrial glioblastoma, non-small cell lung sarcoma, as well brain metastasis. xmlns:xlink="http://www.w3.org/1999/xlink">Results Our learning-based models reached 66.51% balanced accuracy when distinguishing those 6 sites origin 90.5% location-specific dataset where types from close locations were grouped. further investigated an explainable artificial intelligence-based (XAI) -SHAP. They returned set 60 genes highest impact models' decision-making process. xmlns:xlink="http://www.w3.org/1999/xlink">Conclusions results show that deep-learning methods promising opportunity detection could support clinicians' process finding solution black-box problem.

Язык: Английский

Процитировано

8
Epigenetic modifications of cfDNA in liquid biopsy for the cancer care continuum DOI Creative Commons

Jodie Wong,

Rohit Muralidhar,

Liang Wang

и другие.

Biomedical Journal, Год журнала: 2024, Номер unknown, С. 100718 - 100718

Опубликована: Март 1, 2024

This review provides a comprehensive overview of the latest advancements in clinical utility liquid biopsy, with particular focus on epigenetic approaches aimed at overcoming challenges cancer diagnosis and treatment. It begins by elucidating key terms, including methylomics, fragmentomics, nucleosomics. The progresses to discuss methods for analyzing circulating cell-free DNA (cfDNA) highlights recent studies showcasing relevance modifications areas such as diagnosis, drug treatment response, minimal residual disease (MRD) detection, prognosis prediction. While acknowledging hurdles like complexity interpreting data absence standardization, charts path forward. advocates integration multi-omic through machine learning algorithms refine predictive models stresses importance collaboration among clinicians, researchers, scientists. Such cooperative efforts are essential fully leverage potential features practice.

Язык: Английский

Процитировано

6
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy DOI Creative Commons

Baofa Yu,

Shengwen Shao, Wenxue Ma

и другие.

Cancer Letters, Год журнала: 2024, Номер unknown, С. 217350 - 217350

Опубликована: Ноя. 1, 2024

Pancreatic cancer remains one of the most challenging malignancies to treat due its late-stage diagnosis, aggressive progression, and high resistance existing therapies. This review examines latest advancements in early detection, therapeutic strategies, with a focus on emerging biomarkers, tumor microenvironment (TME) modulation, integration artificial intelligence (AI) data analysis. We highlight promising including microRNAs (miRNAs) circulating DNA (ctDNA), that offer enhanced sensitivity specificity for early-stage diagnosis when combined multi-omics panels. A detailed analysis TME reveals how components such as cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix (ECM) contribute therapy by creating immunosuppressive barriers. also discuss interventions target these components, aiming improve drug delivery overcome evasion. Furthermore, AI-driven analyses are explored their potential interpret complex data, enabling personalized treatment strategies real-time monitoring response. conclude identifying key areas future research, clinical validation regulatory frameworks AI applications, equitable access innovative comprehensive approach underscores need integrated, outcomes pancreatic cancer.

Язык: Английский

Процитировано

6
Precision medicine in breast cancer (Review) DOI Open Access
Petros Papalexis, Vasiliki Georgakopoulou, Panagiotis Drossos

и другие.

Molecular and Clinical Oncology, Год журнала: 2024, Номер 21(5)

Опубликована: Авг. 20, 2024

Precision medicine in breast cancer is a revolutionary approach that customizes diagnosis and treatment based on individual tumor characteristics, departing from the traditional one-size-fits-all approach. Breast diverse, with various subtypes driven by distinct genetic mutations. Understanding this diversity crucial for tailored strategies target specific vulnerabilities each tumor. Genetic testing, particularly mutations gene (BRCA) DNA repair-associated genes, helps assess hereditary risks influences decisions. Molecular subtyping guides personalized treatments, such as hormonal therapies receptor-positive tumors human epidermal growth factor receptor 2 (HER2)-targeted treatments. Targeted therapies, including those HER2-positive hormone cancers, offer more effective precise interventions. Immunotherapy, especially checkpoint inhibitors, shows promise, certain triple-negative cancer, ongoing research aiming to broaden its effectiveness. Integration of big data artificial intelligence enhances strategies, while liquid biopsies provide real-time insights into dynamics, aiding monitoring modification. Challenges persist, accessibility complexity, but emerging technologies precision prevention hope improved outcomes. Ultimately, aims optimize efficacy, minimize adverse effects enhance quality life patients cancer.

Язык: Английский

Процитировано

5
The expansion of liquid biopsies to vascular care: an overview of existing principles, techniques and potential applications to vascular malformation diagnostics DOI Creative Commons
Ann Mansur, Ivan Radovanovic

Frontiers in Genetics, Год журнала: 2024, Номер 15

Опубликована: Янв. 18, 2024

Vascular malformations are congenital lesions that occur due to mutations in major cellular signalling pathways which govern angiogenesis, cell proliferation, motility, and death. These have been widely studied oncology substrates for various small molecule inhibitors. Given their common molecular biology, there is now a potential repurpose these cancer drugs vascular malformation care; however, diagnosis required order tailour specific the individual patient’s mutational profile. Liquid biopsies (LBs), emerging as transformative tool field of oncology, hold significant promise this feat. This paper explores principles technologies underlying LBs evaluates revolutionize management malformations. The review begins by delineating fundamental LBs, focusing on detection analysis circulating biomarkers such cell-free DNA, tumor cells, extracellular vesicles. Subsequently, an in-depth technological advancements driving LB platforms presented. Lastly, highlights current state research applying malformations, uses aforementioned techniques conceptualize liquid biopsy framework unique clinical care.

Язык: Английский

Процитировано

4
Identification of serum small non-coding RNA as biomarkers for endometrial receptivity DOI Creative Commons

Shaoyuan Xu,

Dong Hu,

Y.F. Ye

и другие.

Genomics, Год журнала: 2025, Номер 117(2), С. 111002 - 111002

Опубликована: Янв. 21, 2025

Язык: Английский

Процитировано

0
Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review DOI Open Access
Giuliana Ciappina, Enrica Toscano, Alessandro Ottaiano

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 2216 - 2216

Опубликована: Фев. 28, 2025

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with metastatic disease posing significant therapeutic challenges. While anti-EGFR therapy has improved outcomes for patients RAS and BRAF wild-type tumors, resistance major hurdle, limiting treatment efficacy. The concept negative hyperselection emerged as refinement molecular profiling, identifying additional genomic alterations-such HER2 MET amplificationsand MAP2K1 mutations-that predict to agents. Studies incorporating these expanded assessments have demonstrated that nearly half RAS/BRAF tumors harbor alternative biomarkers, underscoring the need selection criteria. Liquid biopsies, particularly circulating tumor DNA (ctDNA) analysis, revolutionized precision oncology by providing minimally invasive, real-time assessment dynamics. ctDNA-based enables detection resistance-associated alterations, guiding decisions greater accuracy than conventional tissue biopsies. Recent trials support predictive value ctDNA-defined hyperselection, revealing superior stratified through liquid biopsy. This narrative review explores evolving role in first-line therapy, emphasizing integration ctDNA refine patient selection, enhance efficacy, pave way personalized strategies CRC.

Язык: Английский

Процитировано

0